Inactive Instrument

News PsyBio Therapeutics Corp. Toronto S.E.

Equities

PSYB

CA5263612098

Summary

Unlock all the news: Be the first to know and act before the market!

PsyBio Therapeutics : Reports Second Quarter 2021 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones	21-08-30	AQ
PsyBio Therapeutics : Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs	21-08-16	AQ
PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs	21-08-16	CI
PsyBio Therapeutics : Adds NMDA Receptor Antagonists and Associated Analogues into its Intellectual Property Portfolio	21-08-04	AQ
PsyBio Therapeutics : CEO and CMO to Participate in Fireside Chat at LifeSci Partners Summer Symposium	21-07-20	AQ
PsyBio Therapeutics : Announces Uplisting to OTCQB Venture Market	21-07-14	AQ
PsyBio Therapeutics : Files Novel Psychedelic Compositions and Methods of Treatment Patent With USPTO	21-07-13	MT
PsyBio Therapeutics : Augments Intellectual Property Portfolio with Filing of Next Novel Psychedelic Compositions and Methods of Treatment Patent	21-07-13	AQ
PsyBio Therapeutics : Announces TSXV Approval of Share Buyback Program	21-06-28	AQ
Psybio Therapeutics Corp. Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds	21-06-22	CI
PsyBio Therapeutics : Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie	21-06-22	AQ
PsyBio Therapeutics Corp. Announces Executive Changes	21-06-01	CI
PsyBio Therapeutics Corp.'s Board intends to launch an Equity Buyback.	21-06-01	CI
PsyBio Therapeutics : Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors	21-04-21	AQ
PsyBio Therapeutics : Retains KCSA Strategic Communications for Investor Relations Services	21-04-09	AQ
PsyBio Therapeutics : Strengthens Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer	21-04-05	MT
PsyBio Therapeutics : Strengthens its Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer	21-04-05	AQ
PsyBio Therapeutics Announces Retention of Market Maker	21-03-04	GL
PSYO THER : PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development and Manufacturing Organization	21-03-02	AQ
PsyBio Announces Second Quarter Financial Results of Leo Acquisition Corp.	21-03-01	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News PsyBio Therapeutics Corp. Toronto S.E.

Equities

PSYB

CA5263612098

Summary

Filters